Bullfrog AI (BFRG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Oct, 2026Executive summary
Virtual special meeting set for October 22, 2025; August 29, 2025 record date, with 10,249,805 common shares outstanding and one vote per share.
Four proposals: Nasdaq-compliant issuance to Lincoln Park, reverse-split authority, a 750,000-share equity-plan increase and meeting adjournment authority; the Board recommends FOR each.
Voting matters and shareholder proposals
Proposal 1 seeks approval to issue 20% or more of outstanding shares under a purchase agreement allowing sales of up to $10 million of common stock to Lincoln Park over 36 months.
Proposal 2 seeks discretionary authority for a 1-for-2 to 1-for-15 reverse split; the Board may implement it by December 31, 2026, or let the authority expire.
Proposal 3 seeks 750,000 additional pre-split plan shares; Proposal 4 would permit adjournment to solicit more votes if needed.
Each proposal requires more votes FOR than AGAINST among votes cast; abstentions do not count as votes cast. Proposals 1 and 3 are expected to be non-routine, so brokers cannot vote uninstructed shares on them.
Stockholders may vote online, by telephone, mail or during the virtual meeting; online and telephone voting closes October 21, 2025 at 11:59 p.m. ET.
Board of directors and corporate governance
The Board unanimously approved the proposals and recommended FOR each; it retains sole discretion over whether and at what ratio to implement the reverse split.
Vininder Singh is Board chair and CEO; five directors and named executive officers collectively beneficially owned 25.16% of common stock as of August 29, 2025.
Latest events from Bullfrog AI
- AI platform targets drug discovery economics, backed by a pharma deal and expanding pipeline.BFRG
LD Micro 20th Annual Main Event Conference - A warrant-resale registration amid early-stage drug development and ongoing funding needs.BFRG
Registration filing - Resale registration could yield up to $3.26M, contingent on cash warrant exercises.BFRG
Registration filing - A $100 million shelf backs an early-stage AI drug strategy facing financing and clinical risks.BFRG
Registration filing - Four directors face election as shareholders consider auditor ratification for FY2025.BFRG
Proxy filing - Four director nominees and M & K auditor ratification anchor the 2024 virtual meeting agenda.BFRG
Proxy filing - Votes cover financing dilution, a discretionary reverse split and a 750,000-share Plan increase.BFRG
Proxy filing - Amendment updates Item 16 and auditor consent; the continuous-offering framework remains.BFRG
Registration filing - A conditional $10 million equity facility brings potential liquidity and substantial dilution risk.BFRG
Registration filing